SQUIDs in biomagnetism: a roadmap towards improved healthcare
Rainer Körber,Jan-Hendrik Storm,Hugh Seton,Jyrki P Mäkelä,Ritva Paetau,Lauri Parkkonen,Christoph Pfeiffer,Bushra Riaz,Justin F Schneiderman,Hui Dong,Seong-min Hwang,Lixing You,Ben Inglis,John Clarke,Michelle A Espy,Risto J Ilmoniemi,Per E Magnelind,Andrei N Matlashov,Jaakko O Nieminen,Petr L Volegov,Koos C J Zevenhoven,Nora Höfner,Martin Burghoff,Keiji Enpuku,S Y Yang,Jen-Jei Chieh,Jukka Knuutila,Petteri Laine,Jukka Nenonen
DOI: https://doi.org/10.1088/0953-2048/29/11/113001
2016-09-19
Superconductor Science and Technology
Abstract:Globally, the demand for improved health care delivery while managing escalating costs is a major challenge. Measuring the biomagnetic fields that emanate from the human brain already impacts the treatment of epilepsy, brain tumours and other brain disorders. This roadmap explores how superconducting technologies are poised to impact health care. Biomagnetism is the study of magnetic fields of biological origin. Biomagnetic fields are typically very weak, often in the femtotesla range, making their measurement challenging. The earliest in vivo human measurements were made with room-temperature coils. In 1963, Baule and McFee (1963 Am. Heart J. 55 95−6) reported the magnetic field produced by electric currents in the heart ('magnetocardiography'), and in 1968, Cohen (1968 Science 161 784−6) described the magnetic field generated by alpha-rhythm currents in the brain ('magnetoencephalography'). Subsequently, in 1970, Cohen et al (1970 Appl. Phys. Lett. 16 278–80) reported the recording of a magnetocardiogram using a Superconducting QUantum Interference Device (SQUID). Just two years later, in 1972, Cohen (1972 Science 175 664–6) described the use of a SQUID in magnetoencephalography. These last two papers set the scene for applications of SQUIDs in biomagnetism, the subject of this roadmap.
physics, condensed matter, applied